Sector News

GSK appeals to parents with latest meningitis B commercial

August 13, 2019
Life sciences

Back to college usually means meningitis vaccine marketing, and that’s exactly what GlaxoSmithKline is doing. It recently boosted its meningitis B awareness push with a second animated commercial added to the rotation for a campaign begun in 2018.

The new TV ad depicts a young woman lying in a dorm bed too sick to even answer her phone. A female voice-over says, “This is not just a headache. This is not just a fever. This is not just the flu. It’s meningitis B, and you’re not there to help.”

Talking directly to parents of college-bound teens, the new ad maintains GSK’s messaging from the ongoing campaign that encourages parents to act. A GSK spokesperson said via email that “the need for education is great” in light of the fact that vaccinations for the rare but serious disease remain low. College students can face a higher risk of meningitis related to their more communal and sharing lifestyle.

Only about half (51%) of pediatricians and 31% of family doctors initiated a conversation about meningitis B during routine visits for 16-to 18-year-olds, according to a study published in Pediatrics magazine last fall.

A recent call to action by seven leading pediatric and family healthcare associations encourages doctors to use 16-year-old checkups as a platform to make sure immunizations are being met, and it includes suggestions for both types of meningitis vaccines.

“The 16-year-old visit is the perfect opportunity for the physician to administer the second dose of the meningococcal conjugate vaccine (MenACWY), the flu vaccine, and discuss the MenB vaccine,” the American Academy of Family Physicians’ president, John Cullen, said in a news release.

GSK makes Bexsero, which competes with the only other meningitis B vaccine on the market, Pfizer’s Trumenba. Bexsero leads in market share, but its sales growth slowed in 2018. GSK reported sales of £584 million, which was a 9% increase over the previous year. In 2017, Bexsero sales of £556 million marked a 34% jump over 2016’s haul. Pfizer reported 2018 Trumenba sales of $21 million, up from $9 million in 2017. Trumenba was approved in October 2014, while Bexsero was approved in January 2015.

“GSK takes seriously our role as a partner in protecting public health and is committed to providing vaccines for vaccine-preventable diseases, including meningitis B,” the GSK spokesperson said. “We are also committed to providing the critical education required for all stakeholders—public health officials, health care providers and patients— about this uncommon but potentially fatal disease so that patients and health care professionals can have discussions about vaccination options.”

By: Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend